![Tai-An Lin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profiel
Tai-An Lin formerly worked at EMD Serono, Inc., as Director-Immuno Oncology Translational from 2016 to 2019, Springworks Therapeutics, Inc., as Chief Scientific Officer from 2023 to 2025, and Black Diamond Therapeutics, Inc., as SVP-Translational Science & Discovery Biology.
Dr. Lin received his doctorate degree from the University of Missouri.
Eerdere bekende functies van Tai-An Lin
| Bedrijven | Functie | Einde |
|---|---|---|
| SPRINGWORKS THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-07-2025 |
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology Develops recombinant prescription medicines | Corporate Officer/Principal | 01-09-2019 |
| BLACK DIAMOND THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Opleiding van Tai-An Lin
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
7
Eerstegraads connecties
4
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
University of Missouri
 University of Missouri Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology Develops recombinant prescription medicines | Health Technology |
Black Diamond Therapeutics, Inc.
 Black Diamond Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops precision medicines for cancer | Health Technology |
Springworks Therapeutics, Inc.
 Springworks Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops and commercializes medicines for nervous system disorders | Health Technology |
